

CADTH REIMBURSEMENT REVIEW

Pharmacoeconomic Report

GENERIC DRUG NAME (BRAND NAME)

(Sponsor)

Indication: Text

Version: 1.0

Publication Date: Month XX, Year

Report Length: 18 Pages

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governments or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Table of Contents

List of Tables	4
List of Figures	5
Abbreviations	6
Executive Summary	7
Conclusions	9
Stakeholder Input Relevant to the Economic Review	10
Economic Review	11
Economic Evaluation.....	11
Issues for Consideration.....	11
Overall Conclusions	11
Appendix 1: Cost Comparison Table	12
Appendix 2: Submission Quality	13
Appendix 3: Additional Information on the Submitted Economic Evaluation	14
Detailed Results of the Sponsor’s Base Case	14
Appendix 4: Additional Details on the CADTH Reanalyses and Sensitivity Analyses of the Economic Evaluation	15
Detailed Results of CADTH Base Case.....	15
Scenario Analyses	15
Appendix 5: Submitted BIA and CADTH Appraisal	16
Summary of Sponsor’s BIA	16
Summary of the Sponsor’s BIA Results.....	16
CADTH Appraisal of the Sponsor’s BIA.....	16
CADTH Reanalyses of the BIA.....	16
References.....	17

List of Tables

Sample Template

List of Figures

Sample Template

Abbreviations

Sample Template

Executive Summary

The executive summary is comprised of two tables (Table 1: Background and Table 2: Economic Evaluation) and a conclusion.

Table 1: Submitted for Review

Item	Description
Drug product	
Submitted price	
Indication	
Health Canada approval status	
Health Canada review pathway	
NOC date	
Reimbursement request	
Sponsor	
Submission history	

Sample Text

Table 2: Summary of Economic Evaluation

Component	Description
Type of economic evaluation	
Target population(s)	
Treatment(s)	
Comparator(s)	
Perspective	
Outcome(s)	
Time horizon	
Key data source	
Submitted results for base case (and key scenario analyses as required)	
Key limitations	
CADTH reanalysis results	

Conclusions

Sample Template

Stakeholder Input Relevant to the Economic Review

Sample Template

Economic Review

Economic Evaluation

Summary of Sponsor's Economic Evaluation

Overview

Model Structure

Model Inputs

Summary of Sponsor's Economic Evaluation Results

Base-Case Results

Sensitivity and Scenario Analysis Results

CADTH Appraisal of the Sponsor's Economic Evaluation

CADTH Reanalyses of the Economic Evaluation

Base-Case Results

Scenario Analysis Results

Issues for Consideration

Overall Conclusions

Appendix 1: Cost Comparison Table

Sample Template

Appendix 2: Submission Quality

Table 3: Submission Quality

Description	Yes	No	Comments
Population is relevant, with no critical intervention missing, and no relevant outcome missing	<input type="checkbox"/>	<input type="checkbox"/>	
Model has been adequately programmed and has sufficient face validity	<input type="checkbox"/>	<input type="checkbox"/>	
Model structure is adequate for decision problem	<input type="checkbox"/>	<input type="checkbox"/>	
Data incorporation into the model has been done adequately (e.g., parameters for probabilistic analysis)	<input type="checkbox"/>	<input type="checkbox"/>	
Parameter and structural uncertainty were adequately assessed; analyses were adequate to inform the decision problem	<input type="checkbox"/>	<input type="checkbox"/>	
The submission was well organized and complete; the information was easy to locate (clear and transparent reporting; technical documentation available in enough details)	<input type="checkbox"/>	<input type="checkbox"/>	

Appendix 3: Additional Information on the Submitted Economic Evaluation

Detailed Results of the Sponsor's Base Case

Sample Template

Appendix 4: Additional Details on the CADTH Reanalyses and Sensitivity Analyses of the Economic Evaluation

Detailed Results of CADTH Base Case

Scenario Analyses

Sample Template

Appendix 5: Submitted BIA and CADTH Appraisal

Key Take-aways of the BIA

-

Summary of Sponsor's BIA

Summary of the Sponsor's BIA Results

CADTH Appraisal of the Sponsor's BIA

CADTH Reanalyses of the BIA

References

Sample Template

Sample Template